L. Ni

Streptococcus agalactiae Inhibits Candida albicans Hyphal Development and Diminishes Host Vaginal Mucosal TH17 Response

Aiping Zhou, Yu-Feng Yao, Jian Guo, 2018, Front. Microbiol..

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.

S. Vermeire, G. D'Haens, D. Gaya, 2022, The lancet. Gastroenterology & hepatology.

105 CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

S. Vermeire, G. D'Haens, D. Gaya, 2021 .

Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial

S. Vermeire, D. Gaya, L. Peyrin-Biroulet, 2020 .

DOP10 Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy

M. D’Agostino, T. Kucharzik, G. Maconi, 2020 .

Early ultrasound response and progressive transmural remission after treatment with ustekinumab in Crohn's disease.

M. D’Agostino, M. Allocca, T. Kucharzik, 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn’s disease: results up to Week 48 of the STARDUST trial

S. Vermeire, G. D'Haens, D. Gaya, 2021 .

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial

S. Vermeire, G. D'Haens, D. Gaya, 2023, United European gastroenterology journal.